Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sapropterin Dihydrochloride Oral Suspension vs Kuvan in Healthy Subjects
NCT06481709Phase 1Completed
- Sponsor
- APR Applied Pharma Research
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sapropterin in phenylketonuria (PKU) (4 arms), sponsored by APR Applied Pharma Research. Primary endpoints: Uncorrected Sapropterin AUC0-t, Baseline-corrected Sapropterin AUC0-t and 4 more. Started Jul 2024; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT06481709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481709.